Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy

Zonisamide treatment was generally well tolerated and was associated with significant reductions in seizure frequency in this pediatric population with a variety of both partial and generalized medically refractory epilepsy syndromes.